The biotech sector has always been one of the more popular sectors for investors for many years and it continues to be so. There continue to be lots of intriguing options in the sector that investors could consider looking into and one of those at this point is Halberd Inc (OTCMKTS:HALB). It is regarded as an innovative biotech company and is involved in developing treatment by virtue of the provisional patent applications, patents, and licenses that it acquires.
Some of the conditions for which Halberd develops treatments include blood-borne diseases, cancer, PTSD and CTD among others. Now that you have a fair idea about Halberd and its operations, it is time to take a look at recent developments in order to get a better idea about the company.
Elimination of Target Antigens, Progressing to Treatments for Neurodegenerative Diseases
Earlier on in the month on January 13, the company was actually in the news after it announced that it had been successful in eliminating Interleukin-4 and Beta-Amyloid from synthetic cerebral spinal fluid in the most recent in-vitro lab testing. It goes without saying that it was a significant development for the company and one that must have cone as a source of optimism for investors as well. It was particularly significant considering the fact that it was one of the long-term goals of Halberd.
Halberd Corporation Now an Official US Government Contractor
While the above-mentioned development was certainly an important one for the company, it is perhaps necessary to point out that earlier on in the month there had been another major development with regards to Halberd. Back on January 5, the company announced that it had been registered with the United States Federal Government’s System for Award Management.
Now that the company has been registered in that system, it is a registered contractor for the United States government. The company can now bid on government contacts freely. As is well known, government contracts can be hugely lucrative, and hence, the registration was a major development for Halberd. At this point in time, it may be a good idea for investors to consider adding the stock to their watch lists and watch out for further developments.
